| Global Research Trends

Friday, 20 August 2021

Pupillometer Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

Pupillometer Market – Regional Insights

On the basis of region, the global Pupillometer Market is segmented into North America, Asia Pacific, Europe, Latin America, Middle East, and Africa. North America accounted for the largest share in the global pupillometer market, owing increasing investments in healthcare sector in U.S., which in turn is expected to boost growth the pupillometer market. For instance, according to article published in Clinical Review & Education, 2018, the U.S. invested around 17.8% of its gross domestic product on health care in 2016, whereas spending in the other countries ranged from 12.4% (Switzerland) to 9.6% (Australia). Moreover, technological advancements in pupillometer is expanding the product portfolio of pupillometer.

Pupillometer or pupilometer are the ocular checking digital instrument used in the ophthalmology and critical care medicine, for measuring the pupil reactivity and distance between pupils. Pupil evaluation in the pupillary information is widely used as an indication for possible medical intervention and patient management. Physicians evaluate the pupil to check and monitor pupillary reflex by examining both the direct and consensual responses, a good response is constriction of both pupils and it indicates healthy cranial nerve pathway. Variation in the response suggests damage to the nerves from drug use, injures or trauma. Moreover, Pupillometer is used for the proper fitting of spectacles so that the lenses are centered in visual axis. Recent pupillometer are handheld infrared portable devices, which provide a consistent and accurate measurement of the symmetry, reactivity, and pupillary size. Digital and automated pupillometers are available in the market depending on the application. These devices are compact and user friendly, which has increased its adoption in the market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1827

Pupillometer Market Dynamics

Advancements and increasing adoption of information technology in new product development is driving growth of the pupillometer market. For instance, Essilor Instruments USA launched X81705 Pupillometer in 2017, which offers accurate measurement with manual control. The X81705 allows manual adjustment of unlimited vision distance from 35 cm to infinity and binocular-monocular measurements. Moreover, X81705 have digital read-outs with measurements to 0.5 nm and features an automatic off/on functions. Furthermore, reliability concerns regarding standard pupillometry practice are boosting growth of the automated pupillometer market. For instance, a study published in 2016, American Journal of Critical Care reported that neurological nurses and critical care consistently underestimated pupil size and incorrectly measured pupil reactivity, which concluded that use of automated pupillometer is essential tool allowing more effective and timely diagnostic. Increasing prevalence of eye disorders across the globe is also contributing to the pupillometer market growth. According to 2017, report of International Council of Ophthalmology, it was estimated that 1.1 billion people have near-vision impairment and 217 million people live with Moderate Or Severe Visual Impairment (MSVI), these cases of MSVI are expected to reach about 588 million people in 2050. Furthermore, prolong exposure to digital electronics such as televisions, smartphones & tablets, laptops, video games, and computers has increased the ophthalmic related disorders, which is driving the growth of pupillometer market. However, lack of skilled professional for operating advance pupillometer device is hindering the pupilometer market growth.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/pupillometer-market-1827

Asia Pacific is projected to witness significant growth over the forecast period, owing to increasing awareness regarding eye disease and increasing prevalence of ophthalmic diseases. For instance, a study published in Delhi Journal of Pathalmology, 2013 revealed that 91 million population is visually impaired in the entire South East Asia region, with almost one third of the global share.

Pupillometer Market – Competitive Landscape

Major players operating in the global pupillometer market include US Ophthalmic, NeurOptics, Inc., Takagi Ophthalmic Instruments, Essilor, Veatch ophthalmic Instruments, Luneau Technology, Good-Lite Co., and AMETEK GmbH. Companies are focused towards adopting market strategies such as launch of new innovative products, mergers, collaborations and acquisition to hold their position in the market and increase product portfolio. For instance, in 2015, Luneau Technology group that develops and manufactures Visionix wavefront-based refraction and diagnostics instruments with AIT Industries, a distributor of ophthalmic instruments and equipment’s based in Bensenville, Illinois.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1827

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Phenylalanine Market Size, Trends, Shares, Insights and Forecast – 2018-2026

Moreover, high prevalence of chronic pain diseases is expected to foster the growth of Phenylalanine Market over the forecast period. For instance, according to the American Academy of Pain Medicine (AAPM), in 2011, around 1.8 billion people suffered from chronic pain. Moreover, the National Institutes of Health (NIH) estimates that one in 10 people in the U.S. suffer from chronic pain. According to a study published in the British Medical Journal in 2016, nearly one-third to half of the population in the U.K. suffers from chronic pain. Moreover, according to the NIH estimates published in 2015 by the American Pain Society, around 50 million people in the U.S. suffered from chronic pain.

Phenylalanine is essential alpha amino acid, which functions to maintain adequate levels of monoamine neurotransmitters in the brain, thereby maintaining balanced moods. Deficiency of phenylalanine causes mental confusion, depression, reduced alertness, memory impairment, and loss of appetite. Phenylalanine is majorly present in three forms: D-Phenylalanine, DL-Phenylalanine, and L-Phenylalanine. L-phenylalanine is natural amino acid found in the proteins, while D-Phenylalanine is synthesized form of phenylalanine, produced in laboratory. DL-phenylalanine is synthetic product made of 50% D-phenylalanine and 50% of L-phenylalanine.

L-phenylalanine is an essential amino acid, which is also an only form of phenylalanine found in proteins. Major dietary sources of L-phenylalanine include meat, fish, eggs, cheese, and milk. L-phenylalanine and DL-phenylalanine are commonly used to treat depression, Attention Deficit-Hyperactivity Disorder (ADHD), chronic pain, and a skin disease called vitiligo.

The primary function of phenylalanine is to produce tyrosine, which further gets converted into three key neurotransmitters: L-dopa, norepinephrine, and epinephrine. As some antidepressants function by increasing levels of norepinephrine, various forms of phenylalanine have been observed as a possible treatment for depression. Furthermore, D-phenylalanine has been found to be effective in the treatment of chronic pain. It blocks enkephalinase, an enzyme which increases pain levels in the body.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1828

Phenylalanine Market Drivers

Increasing prevalence of anxiety and depression are responsible for massive consumptions of anti-depressants, in turn promoting global phenylalanine market growth. For instance, according to the World Health Organization (WHO) data findings, in 2017, over 300 million people of all ages are suffering from depression worldwide, wherein around 800,000 people die due to suicide due to anxiety disorders and depression as prime cause. Moreover, according to the National Institute of Mental Health (NIMH), in 2016, an estimated 10.3 million U.S. adults (4.3% of all U.S. adults) aged 18 or older had at least one major depressive episode with severe impairment. Furthermore, according to the same source, the prevalence of major depressive cases was higher among adult females (8.5%) as compared to males (4.8%). Furthermore, the prevalence of adults with a major depressive episode was highest among individuals aged 18-25 (10.9%). The association (NIMH) also mentions that these disorders are highly treatable thereby propelling opportunities for growth of the global phenylalanine market.

Furthermore, increasing prevalence of pain and chronic diseases such as cancer and others are driving growth of the phenylalanine market. For instance, according to the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer are expected to be diagnosed in the U.S. and 609,640 people are expected to die from the disease.

Phenylalanine Market Restraints

Phenylalanine should be avoided in people with certain inherited disorders such as Phenylketonuria (PKU), where body build up too much phenylalanine. People with phenylketonuria can develop mental retardation, high blood pressure, stroke, and many other serious health issues if they consume phenylalanine. PKU is severe disorder due to which infants are generally screened at birth to determine whether they have the disorder and will need a special diet to avoid these problems.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/phenylalanine-market-1828

Phenylalanine Market – Regional Analysis

Geographically, the global phenylalanine market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Increasing incidence of cancer and rising number of trauma cases worldwide is propelling demand for pain management associated with it. North America phenylalanine market is expected to witness significant growth during the forecast period. As per statistics published by Centers for Disease Control and Prevention (CDC), in 2014, trauma accounts for 41 million visits to the emergency ward each year in the U.S.

Furthermore, developed economies such as the U.S., U.K. and Germany experience high rate of adoption due to better healthcare facilities and easy availability of depression medication in these countries. According to the American academy of pain medicine, every year, over 100 million people suffer from chronic pain, 25.8 million from diabetes, 16.3 million from coronary heart disease, and 11.9 million from cancer in the U.S. This number is expected to further increase in the near future.

Increasing research and development initiatives by various government and non-governmental organizations such as National Institutes of Health (NIH) Brain Research through Advancing Innovative Neurotechnologies (BRAIN), which aims to better understand the human brain and harness the same for various therapeutic applications, including effective pain management, is expected to create a conducive environment for market growth in these region.

Phenylalanine Market – Competitor

Some of the key players operating in the phenylalanine market include Amazing Nutrition, LiftMode (Synaptent LLC), NutraMarks, Inc., NOW foods, healthvit, and Shijiazhuang Jirong Pharmaceutical Co., Ltd.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1828

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Thursday, 19 August 2021

Peptide Therapeutics Market Size, Trends, Shares, Insights and Forecast – 2018-2026

Several peptide therapeutics are used as replacement therapies in order to supplement peptide hormones when endogenous levels are inadequate or absent. Insulin and adrenocorticotrophic hormone (ACTH) are peptides isolated from natural sources, whereas oxytocin and vasopressin are synthetic peptides.

The global Peptide Therapeutics Market is estimated to account for US$ 23,319.3 Mn in terms of value and is expected to reach US$ 57,166.5 Mn by the end of 2027.

Global Peptide Therapeutics Market: Drivers

Increasing adoption of peptide therapeutics is expected to aid in growth of the global peptide therapeutics market over the forecast period. Peptides therapeutics are typically associated with lower production complexity compared with protein-based-biopharmaceuticals. This in turn results in lower production costs, which increases adoption of peptides therapeutics compared to small molecules and biopharmaceuticals.

Global Peptide Therapeutics Market: Opportunities

Development of multifunctional peptides and conjugates is expected to offer lucrative growth opportunities for players in the market. For instance, in February 2019, researchers from University of Milan reported that the polypeptide lunasin derived from bioactive food offered hypocholesterolemic, antioxidant, and anti-inflammatory properties and can be effective in prevention of cardiovascular disease.

Global Peptide Therapeutics Market: Restraints

Therapeutic peptides have low membrane permeability and are prone to hydrolysis and oxidation, which is expected to hinder growth of the market.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1837

Key Takeaways:

The branded sub segment in the product type segment in global peptide therapeutics market was valued at US$ 12,415.2 Mn in 2018 and is expected to reach US$ 27,349.8 Mn by 2027 at a CAGR of 9.1% during the forecast period.

Branded medications in the peptide therapeutics market have extensive patent protections and preferred by the physicians in developed as well as emerging economies. Moreover, branded medications are costly as compared to generic peptide therapeutics.

The cancer sub segment in applications segment held dominant position in the global peptide therapeutics market in 2018, accounting for 34.3% share in terms of value, followed by metabolic disorders and central nervous system disorders, respectively.

Increasing prevalence of cancer is expected to create lucrative opportunities for growth of manufacturers in the market. For instance, according to the National Cancer Institute, 2016, the number of new cancer cases per year is expected to increase to 23.6 million by 2030, worldwide.

The parenteral sub segment in route of administration segment held dominant position in the global peptide therapeutics market in 20148, accounting for 70.4% share in terms of value, followed by transdermal route and mucosal route, respectively.

Vast number of parenteral peptide therapeutics have been launched in the market. These drugs are effective as the drug is directly administered in the blood stream bypassing gastrointestinal tract.

Market Trends

The market is witnessing increasing adoption of peptide therapeutics for the treatment of cancer. For instance, in January 2020, IBicycle Therapeutics plc., a biotechnology that develops therapeutics based on its proprietary bicyclic peptide technology, collaborated with Cancer Research UK for funding in R&D of BT7401, a multivalent Bicycle CD137 agonist for the treatment of cancer.

Major players in the market are focused on collaborating with universities for R&D of new peptide therapeutics. For instance, in 2018, Sapience Therapeutics, Inc., a biotechnology company focused on R&D in peptide therapeutics, collaborated with the University of Bath to discover new therapeutic agents.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/peptide-therapeutics-market-1837

Regulations

Europe

The medicines regulatory authorities of the Member States, or 'national competent authorities', are responsible for the authorisation of medicines available in the EU that do not pass though the centralised procedure.

For clinical trials, European Medicines Agency maintains only EUDRACT and EUDRAVigilance database. The National agency of each country is responsible for conducting the trial.

CHMP or Committee for Medicinal Products for Human use assess the product for marketing approval in EU

In EU, biologic is wide umbrella term that includes peptides

Non-clinical studies are carried out according to ICH-S6 guidelines

There is a centralised MAA procedure; however, biologics are also approved at member state level

Global Peptide Therapeutics Market: Competitive Landscape

Major players operating in the global peptide therapeutics market include, AstraZeneca plc., Bachem Holding AG, CordenPharma International, Eli Lilly and Company, Ipsen S.A, Merck & Co., Inc., Novo Nordisk A/S, PolyPeptide Group, and Teva Pharmaceutical Industries Ltd.

Global Peptide Therapeutics Market: Key Developments

January 2020: Cybrexa Therapeutics, a privately-held biotechnology company focused on development of next-generation tumor-targeted cancer therapies, announced CBX-12 (alphalex exatecan) as the new lead development program. The Cybrexa alphalex technology platform consists of a pHLIP peptide, linker, and small molecule anti-cancer agent.

January 2020: Protagonist Therapeutics, Inc. announced the achievement of a research milestone under its worldwide license and research collaboration agreement with Janssen Biotech, Inc., for co-development and commercialization of PTG-200, an oral, gut-restricted IL-23 receptor antagonist and second generation peptides for the treatment of inflammatory bowel disease.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1837

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

ELISA Analyzer Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

Increasing array of products to ease the workflow is the major factor driving the ELISA Analyzer Market growth over the forecast period. Enzyme Linked Immunosorbent Assay (ELISA) is a biochemical assay, which use antibodies and an enzyme-mediated color change to detect the presence of either antigen (proteins, peptides, and hormones) or antibody in sample. Enzyme-linked immunosorbent assay is used as diagnostic tool in medicine and analytical tool in biomedical research. ELISA analyzer is an instrument used for detecting the concentration and presence of analyte in the test sample. ELISA analyzer can be used are a part of workflow were reagents and consumables are fed to carry out ELISA and results are displayed on the screen attached to it, which is known as automated ELISA analyzer.

Moreover, increasing prevalence of infectious disease and drug development are also expected to fuel the ELISA analyzer market growth over the forecast period. However, stringent regulatory policies for product approval are expected to hinder the new product launches, which in turn is restraining growth of the market.

ELISA Analyzer Market Dynamics

New product launches with increased sophistication and value added testing environment to enhance sensitivity coupled with compactness of product are expected to fuel growth of the ELISA analyzer market over the forecast period. For instance, in 2017, Siemens Healthineers, received CE approval for Atellica Solution, an automated immunoassay and chemistry analyzers in Europe, the U.S., South America, and Asia.

The product has comprehensive menu of 170 assays, which include cardiac, thyroid, and reproductive tests. Furthermore, the company has pipeline of about 50 more assays, which are expected to be added to the present menu. In 2014, Sysmex Corporation launched HISCL-800, a compact and automated immunoassay system used for the immunochemistry testing. The product is claimed to be more compact as compared to other products of same series.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1850

ELISA technique holds promising results in diagnosis of health related problems. High prevalence of infectious disease and cancer are propelling growth of the ELISA analyzer market. For instance, according to World Health Organization (WHO), in 2016, an estimated cases of malaria in 91 countries across the globe were around 216 million, which increased by 5 million as compared to 2015. Moreover, funding and initiatives to eradicate the disease burden are expected to increase the adoption of diagnostic assay and advanced analyzer, in turn augment the ELISA analyzer market growth.

Furthermore, increasing number of drug discovery programs by pharmaceutical and biopharmaceutical companies are propelling demands for improved and advanced instrument to ease with good quality results in less time as a part of the workflow. According to International Federation of Pharmaceutical Manufacturers & Associations, in 2015, new 56 medicines were launched, while currently more than 7,000 compounds are at different stages of development worldwide. Such drug discovery programmes prominently use ELISA in the clinical trial, in turn increasing adoption of ELISA analyzer.

ELISA Analyzer Market - Regional Analysis

Regional segmentation of the market by Coherent Market Insights includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America ELISA analyzer market holds dominant position in global market, owing to increasing burden of infectious disease, adoption of immunoassays in diagnosis, and presence of local market players. For instance, according to National Ambulatory Medical Care Survey, 2015, in the U.S. around 16.8 million visits were reported to physician offices for infectious and parasitic diseases.

However, Asia Pacific ELISA analyzer market is expected to witness rapid growth, owing to increasing demand from emerging economies such as India, where large patient population demands for rapid and high-throughput technology for test and detection of disease.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/elisa-analyzer-market-1850

ELISA Analyzer Market – Competitive Analysis

Key players operating in the ELISA analyzer market include Siemens Healthineers, Awareness Technology, Inc., Dynes Technologies, Inc., EUROIMMUN AG, Robimes, Gold Standard Diagnostics, Corp., BioTek Instruments, Inc., and Berthold Technologies GmbH & Co. KG.

In 2016, Gold Standard Diagnostics, Corp. and R-BioPharma AG collaborated on multiple technology and marketing initiatives to leverages respective strength of both companies to expand product offering and geographic sales coverage. In 2013, Gold Standard Diagnostics, Corp. established distribution partnership for the ThunderBolt automated immunoassay analyzer in 18 countries since its launch in 2012.

Key Development

In August 2019, PerkinElmer, Inc., launched EUROIMMUN Aspergillus Antigen ELISA for detection of aspergillus infections.

In 2017, Siemens Healthineers, received CE mark for Atellica Solution, which is an automated immunoassay and chemistry analyzer and are available in the U.S., Europe, South America, and Asian markets.

In 2014, Sysmex Corporation launched HISCL-800, a compact and automated immunoassay system used for the immunochemistry testing.

In 2012, Dynex Technologies Inc., received china state food and drug administration (SFDA) approval for its DS2 automated enzyme-linked immunosorbent assay (ELISA) analyzer in China. This DS2 assay is considered to be an automated ELISA processing system for clinical diagnostic assays.

In 2012, Gold Standard Diagnostics, Corp. (GSD) launched fully automated ELISA platform thunderbolt

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1850

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Retroperitoneal Liposarcoma Treatment Market Size Share Trends Forecast 2026

Retroperitoneal Liposarcoma Treatment Market – Drivers

The global Retroperitoneal Liposarcoma Treatment Market is expected to exhibit a moderate growth rate, owing to low incidence of this disease across the globe. According to the World Health Organization (WHO) 2016, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and is classified as a rare disease, which accounts for around 17-20% of all the cases (2.5 per Mn population) of sarcoma. Furthermore, rising incidence of genetic disorders is one of the major factors responsible for the global retroperitoneal liposarcoma treatment market growth. According to a report published by the Genetics Education Center, University of Kansas Medical Center, around 15% of all the cancers have an inherited susceptibility and around 12% of the hospital admissions in the U.S. accounted for the treatment of genetic causes in 2013. Various other factors contributing to market growth include changing lifestyle and growing awareness among populace regarding availability of treatment for liposarcoma through initiatives undertaken by various organizations. For instance, Liposarcoma Genome Project initiative by Massachusetts General Hospital Cancer Center conducted research to understand the differences between well-differentiated and de-differentiated liposarcoma, to support the development of treatment for the rare disease. However, high costs associated with the treatment procedures and low accessibility of the treatment due to rareness of the disease are expected to be factors hindering the market growth.

Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous cancer, which occurs in retroperitoneum, lining of the abdominal space that covers the abdominal organs. Retroperitoneal liposarcoma grow continuously and may not get diagnosed until they are very large thus, its prognosis is poor compared to the other subtypes of retroperitoneal sarcomas.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1861

The reason for the development of these tumors are still unknown, however, genetic mutation is considered to be one of the factors leading to the generation of these tumors. Incidence of this disease is equal in men and women, with a slight predominance of men. This tumor has no characteristic symptoms and are usually diagnosed during the advanced stage.

Furthermore, the effectiveness of radiotherapy or chemotherapy for the treatment of this tumor is not properly defined, as they are massive in size and might involve adjacent visceral organs and critical structures. However, affected population who received adjuvant chemotherapy showed survival benefits and improvement, as compared to patients who underwent surgery alone. In the case of surgeries, sometimes, preoperative radiation is given to shrink the tumor. This allows smaller doses of radiation to a smaller field and make the surgery technically more feasible. The European Organisation for Research and Treatment of Cancer (EORTC) is currently conducting a randomized trial comparing 50.4 Gy (Gray-unit to measure radiation therapy) of pre-operative radiation therapy with short-course radiotherapy, followed by surgery to direct surgery alone. Thus, continuous researches that are being conducted for the development of treatment for this disease is expected to create lucrative opportunities in the retroperitoneal liposarcoma treatment market during the forecast period.

Retroperitoneal Liposarcoma Treatment Market - Regional Analysis

On the basis of region, the global retroperitoneal liposarcoma treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds the maximum share for retroperitoneal liposarcoma treatment, owing to increasing research and development of novel therapies and potential drugs for dedifferentiated liposarcoma. For instance, the Sarcoma Foundation of America (SFA) aids sarcoma patients by providing funding for research to private researchers and conducts education campaigns for patients suffering from various types of sarcomas.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/retroperitoneal-liposarcoma-treatment-market-1861

Furthermore, Asia pacific also generates the significant value in retroperitoneal liposarcoma treatment market, owing to the presence of significant population suffering from the disease in this region. For instance, according to the Journal of Blood & Lymph 2013, in India around 35% of the patients suffering from sarcoma died due to dedifferentiated liposarcoma.

Retroperitoneal liposarcoma Treatment Market – Competitor Landscape

Increasing regulatory approvals by the U.S. FDA for various products manufactured by large companies is expected to boost the overall growth of the retroperitoneal liposarcoma treatment market. For instance, in 2015, the U.S. FDA granted priority review for the New Drug Application (NDA) for YONDELIS (trabectedin), manufactured by Janssen Research & Development, LLC to treat patients with advanced soft tissue sarcoma (STS), which includes liposarcoma and leiomyosarcoma subtypes in 77 countries, within North America, Europe, South America, and Asia. Furthermore, in 2016, Eisai Co., Ltd. received the approval in Japan for its in-house developed anticancer agent Halaven (eribulin mesylate) for the treatment of patients suffering from soft tissue sarcoma.

Market players operating in the global retroperitoneal liposarcoma treatment market include Eli Lilly and Company, Baxter International, Bristol Laboratories Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Actavis plc, Fresenius Kabi Ltd., Accord Healthcare Inc., Taro Pharmaceuticals Inc., Sandoz, Bedford Laboratories, and Zydus Cadila.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1861

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Picture Archiving and Communication System (PACS) Market Size Analysis-2027

The Global Picture Archiving and Communication System (PACS) Market, by Deployment (Web Based, Cloud Based and On Premise), by Product (Mid End PACS, Enterprise PACS and Mini PACS), by End User (Hospitals, Clinics, Diagnostics Centers and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1.7 billion in 2017 and is projected to exhibit a CAGR of 5.5% over the forecast period (2018 – 2026).

The Picture Archiving and Communication System (PACS) market is expected to gain significant traction, due to increasing demand for healthcare IT platforms. Increasing demand for healthcare IT is expected to drive growth of the market Improvements in the healthcare IT field, such as the introduction of PACS and cloud computing have provided a new prospect to the healthcare providers and hospital to improve patient centricity by boosting operational efficiencies. Various government initiatives to promote electronic data sharing and EHR adoption will allow healthcare providers to improve the clinical outcomes, with streamlining workflow. In 2009, Health Information Technology for Economic and Clinical Health (HITECH) Act, has provided over US$ 35billion incentives to expand and encourage the adoption and use of EHRs by health care professionals and hospitals. Moreover, increase in the competition among hospitals has made it necessary for management to take appropriate measures increase their efficiency with the integration of these systems at all levels.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1872

Furthermore, the rapidly mounting geriatric population base is demanding healthcare information systems such as PACS to meet the medical requirements. According to a NIH report, in 2015, 8.5% of people were aged 65 and over. This percentage is expected to reach around 17% of the world’s population by 2050. Moreover, healthcare IT companies are continuously funding the development of new and advanced solutions. The advent of these solutions is, thus, providing growth opportunities in PACS market.

Browse 39 Market Data Tables and 28 Figures spread through 180 Pages and in-depth TOC on “Picture Archiving and Communication System (PACS) Market, by Deployment (Web Based, Cloud Based and On Premise), by Product (Mid End PACS, Enterprise PACS and Mini PACS), by End User (Hospitals, Clinics, Diagnostics Imaging Centers and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026”

Key players are focusing on new product launches and improvements in existing ones in order to accelerate business growth. For instance, in June, 2015, Ricoh India, a leader in the field of Imaging Solutions, launched its fully integrated cloud-enabled PACS solution ‘Picasso’. This new solution will provide access of medical images to clinicians and patients, along with reducing the cost of providing medical care. In 2017, FUJIFILM Medical Systems U.S.A., Inc., a leading provider of diagnostic imaging and medical informatics products, launched version 5 of Synapse PACS in the U.S. Synapse 5 is one component of Fujifilm’s comprehensive enterprise imaging portfolio which includes RIS, 3D, Cardiovascular, Enterprise Viewer, Synapse VNA, and cloud services.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/picture-archiving-and-communication-system-pacs-market-1872

Key Takeaways of the Picture Archiving and Communication System (PACS) Market:

The global picture archiving and communication system (PACS) market is expected to exhibit a CAGR of 5.5% over the forecast period, owing to increasing adoption of health IT among healthcare providers.

Among deployment, the cloud based segment holds a dominant position in the picture archiving and communication system (PACS) market, owing to more imaging modalities demanding cloud-based PACS

Among product, the mid end PACS segment holds a dominant position in the picture archiving and communication system (PACS) market, owing to increase in adoption rate and growing demand for integrated solutions Among end user, hospitals segment holds a dominant position in the picture archiving and communication system (PACS) market, owing to increased usage in hospitals for imaging

North America picture archiving and communication system (PACS) market is expected to exhibit significant growth, owing to large number of hospitals and imaging centers using imaging techniques

Key players operating in the global picture archiving and communication system (PACS) market include Agfa-Gevaert Group, Carestream Health, FUJIFILM Medical Systems, INFINITT Healthcare Co. Ltd., GE Healthcare, Koninklijke Philips N.V., Merge Healthcare Solutions Inc., Mckesson Corp., Sectra AB and Siemens Healthineers.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1872

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Biochemistry Analyzers Market To Reach US$ 5,429.5 Million By 2027 - Coherent Market Insights

Biochemistry analyzers are used research purposes and for diagnosis of various diseases. It is also used in analysis of many cellular processes and to determine the structure of a biomolecules. There are two types of biochemistry analyzers depending on modality: bench-top and floor-standing. It is used in clinical diagnostics, bioreactor byproduct detection, and drug development applications.

The global Biochemistry Analyzers Market is estimated to account for US$ 3,716.8 Mn in terms of value in 2020 and is expected to reach US$ 5,429.5 Mn by the end of 2027.

Global Biochemistry Analyzers Market: Drivers

Increasing number of clinical trials is expected to propel growth of the global biochemistry analyzers market over the forecast period. For instance, according to the U.S. National Library of Medicine, the number of clinical trials conducted in the U.S. increased from 30,978 in 2018 to 32,523 in 2019.

Global Biochemistry Analyzers Market: Opportunities

Increasing prevalence of pandemic diseases is expected to boost demand for biochemistry analyzers. For instance, in April 2020, the government of Haiti requested China medical inputs of US$ 18 million, which included 2.5 million gloves, 300,000 sterilized gowns, 10 biochemistry automatic analyzers, 100 ventilators and accessories, and 1,500 hospital beds, for the treatment of COVID-19.

Global Biochemistry Analyzers Market: Restraints

Presence of several laws regulation diagnostic labs in developed economies is expected to limit growth of the market. In the U.S., there are following laws:

Laboratory Accreditation: Internal Quality Control (IQC)

The Internal Quality Control measurement is the final check of the implementation of all the analytical procedures as prescribed in the protocol as well as other quality assurance measurements

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1873

Laboratory Accreditation: External Quality Assessment Scheme (EQAS)

External Quality Assessment for medical laboratories is also known by the name proficiency testing for clinical laboratories and clinical pathology. The use of External Quality Assessment is widely used outside the clinical laboratories for point-of-care testing

The Clinical and Laboratory Standards Institute (CLSI) Guidelines

The Clinical and Laboratory Standards Institute creates voluntary standards and guidelines in respect to the clinical and laboratory testing used within the medical testing and healthcare communities. The standards are accredited by the American National Standards Institute (ANSI)

Key Takeaways:

The global biochemistry analyzers market was valued at US$ 3,520.5 Mn in 2019 and is forecast to reach a value of US$ 5,429.5 Mn by 2027 at a CAGR of 5.6% between 2020 and 2027. Increasing number of drug development activities, and increasing prevalence of chronic disorders is expected to aid in growth of the market.

Fully automated biochemistry analyzers held dominant position in the global biochemistry analyzers market in 2019, accounting for 85.6% share in terms of value, followed by Semi automated biochemistry analyzers, respectively. Fully automated biochemistry analyzers do not require constant manual attention, and they can perform tasks automatically.

Clinical diagnostics segment held dominant position in the global biochemistry analyzers market in 2019, accounting for 82.8% share in terms of value, followed by drug development applications and others, respectively. Increasing prevalence of metabolic diseases, and other chronic diseases is expected to support growth of the segment over the forecast period.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/biochemistry-analyzers-market-1873

Market Trends

Major players in the market are focused on launching products for mid-volume laboratories. For instance, in October 2019, Beckman Coulter launched its new DxH 690T hematology analyzer for mid-volume laboratories.

Major players in the market are also focused on adopting collaboration and partnership strategies to enhance their market share. For instance, in October 2019, Abbott Laboratories partnered with Australian Red Cross Blood Service for its blood and plasma screening technology, Alinity s System.

Global Biochemistry Analyzers Market: Competitive Landscape

Major players operating in the global biochemistry analyzers market include, Roche Diagnostics GmbH, Siemens AG, Beckman Coulter Inc., Abbott Diagnostics Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Hologic, Inc., Randox Laboratories Ltd., Awareness Technology, Inc., Transasia Biomedicals Ltd., and Nova Biomedical Corp.

Global Biochemistry Analyzers Market: Key Developments

November 2019: Mindray Bio-Medical Electronics Co., Ltd. demonstrated its product portfolio at MEDICA 2019

September 2019: Randox Laboratories launched a new online store with exclusive offers and discounts

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1873

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Wednesday, 18 August 2021

Freeze Drying Equipment Market Size, Trends, Shares, Insights and Forecast – 2018-2026

Freeze-drying equipment help to maintain various parameters such as physical state, aroma, and chemical properties. Major application areas of freeze-drying equipment are food preservation, packaging, pharmaceuticals, surgical procedures, and biotechnology.

Statistics:

The global Freeze-Drying Equipment Market is estimated to account for US$ 68,817.1 Mn in terms of value by the end of 2027.

Global Freeze-drying Equipment Market: Drivers

Increasing adoption of freeze-dryers is expected to propel growth of the global freeze-drying equipment market over the forecast period. For instance, in February 2020, LSNE Contract Manufacturing, a contract development and manufacturing organization, broke ground on a 26,000 square foot addition of its existing 7 Commerce facility on the Bedford, New Hampshire campus, which features a high-speed six head Bausch+Ströbel aseptic vial filling line, Ziel isolator, and multiple large-scale commercial freeze-dryers with automated loading/unloading.

Global Freeze-drying Equipment Market: Opportunities

Increasing investment for R&D in lyophilization is expected to offer lucrative growth opportunities for players in the global freeze-drying equipment market. For instance, in May 2020, The National Institute for Innovation in Manufacturing Biopharmaceuticals announced approximately US$ 10 million in funding for 14 new projects, including ‘Automated Process Control of Pharmaceutical Lyophilization: PAT Enabled Freeze-Dryer’.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1876

Global Freeze-drying Equipment Market: Restraints

High setup and processing cost is expected to hinder growth of the market. The freeze-drying process includes various steps such as freezing, exposure to vacuum chamber, drying, and others. This not only increases the cycle time of the process but also the processing cost. The process utilizes a variety of freezing processes that are not required in conventional drying processes such as in desiccant drying. The vacuum assembly consumes more energy as compared to conventional processes, which in turn contributes to processing costs.

Key Takeaways:

The global freeze-drying equipment market was valued at US$ 30,979.7 Mn in 2019 and is forecast to reach a value of US$ 68,817.1 Mn by 2027 at a CAGR of 10.5% between 2020 and 2027. Increasing adoption of freeze-dryers is expected to propel growth of the global freeze-drying equipment market over the forecast period

Industrial Freeze-Dryers segment held dominant position in the global freeze-drying equipment market in 2019, accounting for 35.5% share in terms of value, followed by Laboratory Freeze-Drying Equipment and Benchtop Freeze-Dryers, respectively. Rapidly increasing pharmaceutical sector in developing economies such as India is expected to increase demand for freeze drying equipment,

Market Trends

Major players in the market are focused on adopting approaches to monitor the global batch temperature during primary drying in GMP industrial freeze-dryers. For instance, in November 2019, Telstar incorporated Lyometrics, a soft-sensor temperature monitoring system in GMP industrial freeze-dryers with automatic loading/unloading systems.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/lyophilization-freeze-drying-equipment-market-1876

Major players in the market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in October 2019, SP Industries, Inc. acquired Irta Dosificacio I Technologia S.L. i-Dositecno, a provider of complete sterile filling lines for pharmaceutical, cosmetic, and ophthalmic applications.

Global Freeze-drying Equipment Market: Competitive Landscape

Major players operating in the global freeze-drying equipment market include, Cuddon Engineering Ltd., Freezedry Specialties, Inc., GEA Group, IMA Life The Netherlands B.V., Labconco Corporation, SP Industries, Inc., Telstar, Thermo Fisher Scientific Inc., MechaTech Systems Ltd., Millrock Technology Inc., Zirbus Technology GmbH, Biopharma Process Systems Ltd., LTE Scientific Ltd., Martin Christ GmbH, Shanghai Tofflon Science and Technology Co., Ltd., and OPERON.

Global Freeze-drying Equipment Market: Key Developments

June 2019: Millrock Technology Inc. partnered with Purdue University on a National Science Foundation funded project to develop real-time sensor technologies, computational modeling, and bioanalytical tools for closed-loop lyophilization

April 2019: Telstar launched a new single-vessel GMP production freeze-dryer optimized to maintain conventional work space

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1876

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Artificial Bone Market Size, Share, Outlook, and Opportunity Analysis, 2019– 2027

Global Artificial Bone Market, by Material (Ceramics, Composite, Polymer, Hydroxyapatite, and Others), by Application (Spinal Fusion, Dental, Craniomaxillofacial, Joint Reconstruction, and Trauma and Extremities), by End User (Hospitals, Specialty Clinics, and Research Organization), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 1,375.1 million in 2021 and is expected to exhibit a CAGR of 5.6% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.

Global Artificial Bone Market- Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one of the sectors, which has been majorly impacted by the COVID-19 pandemic. The lockdown in various countries due to the COVID-19 pandemic has created an economic burden on the private healthcare sectors. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety in treatment of patients with other diseases, and declining outpatient’s visits, etc. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Supply chain and manufacturing activities in India, China, and the U.S. have been disrupted due to the global lockdowns, while countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of bone graft substitutes.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1899

Thus, impact of the coronavirus (COVID-19) pandemic is expected to limit growth of the global artificial bone market during the forecast period.

The increasing number of product approvals from regulatory authorities such as USFDA is expected to drive growth of the global artificial bone market during the forecast period. For instance, in September 2020, Baxter International Inc., a global provider in advancing surgical innovation, announced the U.S. Food and Drug Administration (FDA) clearance of its Altapore Shape Bioactive Bone Graft, the latest addition to the company’s next-generation bone graft substitute product line.

The increasing number strategic acquisitions is expected to provide huge opportunities to the global artificial bone market growth in the near future. For instance, in June 2016, Zimmer Biomet Holdings, Inc. acquired LDR Holding Corporation, in stock deal of around US$ 1 billion. LDR Holding Corp. is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders.

The increasing number of technological developments in artificial bones is expected to drive the market growth. Major players in the market are focused on developing novel technological platforms in artificial bone to expand their product portfolio. For instance, according to the data published in Science Daily Journal, in August 2017, researchers from University of British Columbia, Canada developed a new artificial bone design that can be customized and made with a 3-D printer for stronger, safer, and highly effective bone replacements.

Moreover, the chances of having bone related diseases in geriatric population is higher. Thus, increasing number of geriatric population is expected to drive the market growth during the forecast period. For instance, according to a report published in March 2016 by the United States Census Bureau, the geriatric population (aged 65 years and above) is expected to account for 12% of the global population by 2030 and further to 16.7% by 2050, as compared to 8.5% in 2015.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/artificial-bone-market-1899

Browse 35 Market Data Tables and 36 Figures spread through 208 Pages and in-depth TOC on Global Artificial Bone Market, by Material (Ceramics, Composite, Polymer, Hydroxyapatite, and Others), by Application (Spinal Fusion, Dental, Craniomaxillofacial, Joint Reconstruction, and Trauma and Extremities), by End User (Hospitals, Specialty Clinics, and Research Organization), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2028"

The increasing number of clinical trials to develop synthetic bone graft for the treatment of the bone deformity due to trauma and other conditions is expected to drive growth of the global artificial bone market. For instance, in June 2018, Ceramisys Ltd initiated the clinical trial study of the safety and efficacy of the synthetic bone graft substitutes for the treatment of the bone deformity due to trauma and other conditions.

Key Takeaways of the Global Artificial Bone Market:

The global artificial bone market is expected to exhibit a CAGR of 5.6% during the forecast period (2021-2028), owing to the increasing number of product launches, which is expected to propel growth of the market during the forecast period. For instance, in 2015, Stryker Corporation's Spine and Trauma & Extremities Divisions launched BIO4, a new therapeutic alternative to autograft for foot and ankle surgery, which avoids secondary surgical sites necessary to harvest autograft tissue.

Among material segment, ceramics segment is expected to drive the market growth owing to increasing new launches in the market. For instance, in 2018, NuVasive, Inc. launched AttraX Scaffold, an absorbent ceramic-collagen bone graft with an optimized surface.

Major players operating in global single-use products in biopharmaceutical market include Medtronic Plc., Johnson & Johnson, Baxter International Inc., Smith & Nephew plc, Stryker Corporation, NuVasive, Inc., Allosource, Curasan, Inc., Ziacom Medical SLU, Orthofix International N.V., Biomatlante, and DSM.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1899

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737

Medical Grade Hydrogel Market Size Share Trends Forecast Analysis - 2026

Regional Insights

On the basis of Geography, the global Medical Grade Hydrogel Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to lead the medical grade hydrogel market during forecast period, owing to high number of plastic and reconstructive surgeries that are performed annually in which hydrogels based material is extensively used. According to report published by American Society of Plastic Surgeons 2017, around 290,467 breast augmentation surgeries were performed in 2016, which increased to 300,378 in 2017. High prevalence of the chronic disease such as cancer and cardiovascular disease and extensive research and development by pharmaceutical and biotech companies for development of innovative products are driving market growth. According to the estimation of Pharmaceutical Research and Manufacturers of America (PhRMA), in 2017, pharmaceutical industry invested around US$ 0.8 billion to US$ 1.7 billion per company on research and development activities. Europe is projected to witness significant growth in the medical grade hydrogel market.

Hydrogel are hydrophilic, three dimensional, and cross-linked polymer chain, which has property to absorb different fluids. They resemble body tissue with respect to their ability to absorb large amount of water. The property to absorb different types of the fluid makes hydrogel suitable for many medical applications. As human body consist of large amount of water, therefore hydrogels are highly biocompatible and can be used as carrier for many active ingredients. Being biodegradable, hydrogels are harmless as compared to other polymers. Hydrogels such as polysaccharides and polypeptides are of natural origin, whereas artificial hydrogels include N-isopropyl acrylamide and Jeffamine M-1000 acrylamide. Artificial hydrogels carries superior mechanical strength, longer shelf life, and larger capacity to absorb water. This hydrogels are based on the type of material from which they originate, shows varying response to pH, temperature, light, and different chemicals. The pH responsive hydrogels possess chemical/physical properties at specific pH. Gastric targeted drug such as small intestine, stomach, and colon targeted drug delivery system has been under development specifically for chronic conditions such as colon and stomach cancer. Cell modelling is conducted to mimic GI tract cell, based on pH characteristics. Light responsive hydrogels can be used in gene delivery, drug delivery, and biomedical sensors.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1906

Market Dynamics

Medical grade hydrogel is gaining significant traction as the novel carrier, which can be used in various products targeted for different indications. Currently medical grade hydrogel has major application in wound dressings, plastic surgery, cosmetics, orthopedics, and immunotherapy. Increasing research on utility and capability of medical grade hydrogel is expected to propel growth of the medical grade hydrogel market. Hydrogels is currently widely used as material for plastic and reconstructive surgery. Therefore, increasing number of reconstructive surgery is expected to drive growth of market. Extensive research is being conducted on hydrogels for their application in novel drug delivery systems such as controlled release delivery and sustained release delivery to improve the prospect of hydrogels as novel excipient and carrier. Moreover, high prevalence of chronic disease such as cancer is propelling growth of the market. For instance, according to the data published by International Journal of Pharma Sciences and Research (IJPSR), around 9 million deaths occurred due to cancer in 2015, and around 11.4 million people are estimated to die due to cancer by 2030. Such high number of deaths is propelling demand for development of novel molecule with effective targeting of drug towards diseased organ, which can be achieved with hydrogel due to its extracellular characteristics, which would also decrease side effects associated to anti-cancer drugs. Hydrogel act as an effective carrier in skin cancer. Hydrogel such as hyaluronic acid is used as tissue filler for plastic reconstruction surgery such as breast reconstruction. This surgery is conducted if breast cancer treatment compels to remove affected tissue mass. Increasing adoption of immunotherapy to treat various disease such as asthma and Crohn’s disease are expected to fuel growth of the medical grade hydrogel market. A nanovector composed of peptide-based nanofibrous hydrogel can condense DNA to result in strong immune responses against disease such as HIV. HIV is one of the major cause of deaths globally.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/medical-grade-hydrogel-market-1906

According to UNAIDS factsheet, in 2016, around 36.7 million were suffering from HIV worldwide. Hydrogels are majorly used in proteomics and electrophoresis as replacement to other types of polymers. Smart hydrogels and tissue engineering are future research areas for hydrogel, which would aid in medical application and drive growth for medical grade hydrogel market.

Competitive Landscape

Key players operating in the medical grade hydrogel market include 3M, ConvaTec, Integra Lifescience Holdings Corporation, Smith & Nephew plc, United Axelgaard, Coloplast, Paul Hartmann, Medtronic plc, and Ocular Therapeutix.

Companies are launching novel products in order to gain larger market share and establish dominance over other competitors. For instance, Integra LifeSciences launched hydrogel-based product named Revize/Revize-X Collagen Matrix for Plastic and Reconstructive Surgery in October 2017.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1906

About Coherent Market Insights:

Contact Us:

mailto:sales@coherentmarketinsights.com

U.S. Office:

Name: Mr. Shah

Coherent Market Insights 1001 4th Ave,

# 3200 Seattle, WA 98154, U.S.

US : +1-206-701-6702

UK : +44-020-8133-4027

JAPAN : +050-5539-1737